Figure 4. Effect of Mmp12 deletion on aortic wall complement deposition.
A, B. Representative images of immunofluorescence staining and quantification of C3 deposits (red) in suprarenal abdominal aorta of Apoe−/− and Mmp12−/−/Apoe−/− (A), and wild type (WT) and Mmp12−/− (B) mice. Nuclei are stained with DAPI in blue. n = 5 per group. Scale bar: 500 μm. C, D. Plasma C3 and C5a levels of Apoe−/− and Mmp12−/−/Apoe−/− (C), and WT and Mmp12−/− (D) mice. n = 5 to 10 per group. E, F. Plasma C3 levels in Mmp12−/−/Apoe−/− (E) and Mmp12−/− (F) mice at baseline and 9 days of treatment with IgG-FH1–5 or MOPC antibody (control). n = 5 per group. G, H. Representative images of immunofluorescence staining and quantification of C3 (red) in suprarenal abdominal aorta of Mmp12−/−/Apoe−/− (G) and Mmp12−/− (H) mice after 9 days of treatment with IgG-FH1–5 or MOPC antibody (control). n = 5 per group; Scale bar: 500 μm. I, J. Representative images of immunofluorescence staining and quantification of Cit-H3 (red) in suprarenal abdominal aorta of Mmp12−/−/Apoe−/− (I) and Mmp12−/− (J) mice after 9 days of treatment with IgG-FH1–5 or MOPC antibody (control). n = 4 to 5 per group. Scale bar: 500 μm. *P < 0.05, **P < 0.01, ****P < 0.0001 by two-tailed Mann-Whitney U test (A-J).